Mon.Dec 09, 2024

article thumbnail

ASHP Midyear: Nearly Half of Adults With Epilepsy Use CBD Products

Pharmacy Times

Adults with epilepsy are underrepresented in most CBD trials, including common etiologies.

149
149
article thumbnail

Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill

Pharmaceutical Technology

Shares in WuXi AppTec, one of those implicated in the Chinese biotech blacklisting legislation, surged following the omission.

118
118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Pharmacy Times

The phase 3 CEPHEUS trial demonstrated that adding daratumumab (DARA) to the VRd regimen significantly improves minimal residual disease negativity, progression-free survival, and overall response in transplant-ineligible or transplant deferred patients with newly diagnosed multiple myeloma, establishing a new standard of care.

139
139
article thumbnail

Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma

STAT

This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions,  sign up here. Welcome back, ASH followers. Here’s your rundown of Monday’s news.

113
113
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

ASH 2024: Circulating Tumor Cells Can Serve as Biomarker for Poor Outcomes in Multiple Myeloma

Pharmacy Times

Luca Bertamini, MD highlights the potential clinical implications of using circulating tumor cells as a biomarker in patients with newly-diagnosed multiple myeloma.

132
132
article thumbnail

STAT+: Young biotech venture firm raises $500 million for its second fund

STAT

What happens when two computer scientists and a former stem cell researcher become friends while working their way up the venture capital corporate ladder and decide to start their own firm? Well, in Dimension’s case, they end up investing in some buzzy AI startups, counseling pharmaceutical companies, ribbing one another about expense reports, and — as of Monday — are able to raise $500 million for their second fund.

More Trending

article thumbnail

Citryll gains Series B funds to develop NET-targeting antibody

Pharmaceutical Technology

Citryll has secured an oversubscribed Series B funding round, raising 85m ($89.8m) to advance the clinical development of CIT-013.

104
104
article thumbnail

ASHP Midyear: Pharmacists Must Proactively Consider and Implement AI Tools

Pharmacy Times

Although challenges and obstacles persist, artificial intelligence could help rural and smaller pharmacies close gaps in care.

116
116
article thumbnail

Slideshow: Pharmacist’s Role in Infectious Disease Management | ASHP Midyear

Drug Topics

Pharmacist inclusion in infectious disease care teams leads to better patient outcomes.

98
article thumbnail

Phase 3 GMMG-HD7 Trial: Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma

Pharmacy Times

The GMMG-HD7 trial evaluated the addition of isatuximab to standard induction therapy in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation, demonstrating significantly higher rates of minimal residual disease negativity and improved progression-free survival (PFS).

107
107
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Virtual Care Provides Similar Outcomes for Patients with Diabetes | ASHP Midyear

Drug Topics

Research also showed that the percentage of no-show appointments was slightly higher in a pre-virtual group compared to a post-virtual group.

98
article thumbnail

FDA Accepts NDA for Paltusotine to Treat Adult Patients With Acromegaly

Pharmacy Times

If approved, the treatment will be the first and only once-daily, oral selective somatostatin receptor type 2 nonpeptide agonist available for acromegaly.

FDA 89
article thumbnail

Pharmacist-Led Care Leads to Better Outcomes in ASCVD | ASHP Midyear

Drug Topics

Patients with ASCVD experienced a more significant reduction in LDL-C.

98
article thumbnail

Does drinking water lower blood pressure?

The Checkup by Singlecare

Hypertension, or high blood pressure , affects nearly half of American adults. According to the Centers for Disease Control and Prevention (CDC) , only one in four have the condition under controland thats a problem. Why? Hypertension increases your risk of heart disease and stroke, the leading causes of death in the United States. Many factors influence blood pressure, from dietary choices and physical activity levels to how well you manage stress.

89
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

The Importance of Pharmacy-Sponsored Programs for Driving Medication Adherence

Drug Topics

A.J. Lipka discusses the impact of pharmacy-sponsored programming.

98
article thumbnail

Biosecure Act MIA from US defense bill in key win for China biopharma service providers

Fierce Pharma

84
article thumbnail

How Nonstatin Therapies Can Optimize Patients’ Cardiovascular Health | ASHP Midyear

Drug Topics

John Bucheit, PharmD, discussed lipid-lowering medications and how nonstatins can be beneficial for cardiovascular health.

98
article thumbnail

Relief for Chinese biotechs as BIOSECURE Act delayed

pharmaphorum

80
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

HPV Vaccine Programming More Cost-Effective for Patients Under 26

Drug Topics

Researchers analyzed the expansion of HPV vaccination for mid-adults defined as people 26 years or older with increased HPV risk.

article thumbnail

Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide

PharmaVoice

75
article thumbnail

Barriers to CGM Uptake Among Patients, Providers | ASHP Midyear

Drug Topics

A discussion with Kevin Cowart, PharmD, MPH, BCACP, FCCP, BCPS, assistant professor at the University of South Florida Taneja College of Pharmacy.

98
article thumbnail

Fresh from IPO, obesity drug developer BioAge hits a hurdle

pharmaphorum

75
article thumbnail

Challenges in Creating a Sustainable Pharmacy Workforce in Rural Areas | ASHP Midyear

Drug Topics

A discussion with Brittany Norton, PharmD, director of ambulatory care at Sutter Health.

98
article thumbnail

Penn Medicine teams up with Mark Cuban Cost Plus Drug Company

Fierce Healthcare

75
article thumbnail

HIV Care Creates Opportunities for Pharmacists to Expand Scope

Drug Topics

In the most recent episode of Over the Counter, Jay Holloway, PharmD, AAHIVP, discussed advancements in HIV, especially regarding the role of pharmacists.

98
article thumbnail

Amgen's Blincyto keeps 96% of pediatric leukemia patients alive and disease-free in 'practice changing' 3-year study

Fierce Pharma

75
article thumbnail

SGLT2 Inhibitor Outcomes Vary When Stratified By Patient Race | ASHP Midyear

Drug Topics

Efficacy data for dapagliflozin and empagliflozin in a group of Asian patients were evaluated.

76
article thumbnail

ASH: Regeneron plays its PNH hand

pharmaphorum

74
article thumbnail

Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain'

Fierce Pharma

74
article thumbnail

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma

pharmaphorum

74
article thumbnail

ASHP Midyear: Expert Discusses Strategies for Recruitment, Retention, and Interprofessional Collaboration for Rural Pharmacies

Pharmacy Times

The primary challenge facing rural pharmacies include recruitment and retention of staff, the need for pharmacists to handle multiple roles and expertise, and the impact of burnout and stress.

73
article thumbnail

Novo’s $16.5bn Catalent deal cleared by EU Commission

pharmaphorum

73
article thumbnail

ASH 2024: Expert Highlights Bolstered MRD Negativity, Survival With D-VRd in Newly-Diagnosed Multiple Myeloma

Pharmacy Times

Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible.

65